MedPath
Found 15 clinical trials|View Analysis
Sort by:

Eltanexor and Venetoclax in Relapsed or Refractory Myelodysplastic Syndrome and Acute Myeloid Leukemia

Phase 1
Recruiting
Conditions
Relapsed Myelodysplastic Syndrome
Refractory Myelodysplastic Syndrome
Acute Myeloid Leukemia
Recurrent Acute Myeloid Leukemia
Refractory Acute Myeloid Leukemia
Interventions
Drug: Eltanexor
Drug: Venetoclax
Procedure: Bone Marrow Aspiration and Biopsy
Procedure: Biospecimen Collection
First Posted Date
2024-05-06
Last Posted Date
2024-10-17
Lead Sponsor
Vanderbilt-Ingram Cancer Center
Target Recruit Count
60
Registration Number
NCT06399640
Locations
🇺🇸

Vanderbilt University/Ingram Cancer Center, Nashville, Tennessee, United States

A Safety, Tolerability and Efficacy Study of NC525 in Subjects with Advanced Myeloid Neoplasms

Phase 1
Active, not recruiting
Conditions
Relapsed or Refractory Chronic Myelomonocytic Leukemia
Relapsed or Refractory Myelodysplastic Syndrome
Relapsed or Refractory Acute Myeloid Leukemia
Interventions
Drug: NC525
First Posted Date
2023-03-28
Last Posted Date
2024-11-11
Lead Sponsor
NextCure, Inc.
Target Recruit Count
63
Registration Number
NCT05787496
Locations
🇺🇸

City of Hope, Duarte, California, United States

🇺🇸

University of Miami, Miami, Florida, United States

🇺🇸

Massachusetts General Hospital, Boston, Massachusetts, United States

and more 8 locations

Venetoclax and Decitabine in Treating Participants With Relapsed/Refractory Acute Myeloid Leukemia or Relapsed High-Risk Myelodysplastic Syndrome

Phase 2
Active, not recruiting
Conditions
Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome
Recurrent Chronic Myelomonocytic Leukemia
Refractory Blastic Plasmacytoid Dendritic Cell Neoplasm
Acute Myeloid Leukemia
Blastic Plasmacytoid Dendritic Cell Neoplasm
Chronic Myelomonocytic Leukemia
Mixed Phenotype Acute Leukemia
Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm
Recurrent Mixed Phenotype Acute Leukemia
Refractory Acute Myeloid Leukemia
Interventions
Drug: Decitabine
Other: Laboratory Biomarker Analysis
Drug: Venetoclax
First Posted Date
2018-01-19
Last Posted Date
2024-06-20
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
235
Registration Number
NCT03404193
Locations
🇺🇸

M D Anderson Cancer Center, Houston, Texas, United States

Recombinant EphB4-HSA Fusion Protein and Azacitidine or Decitabine for Relapsed or Refractory Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia Patients Previously Treated With a Hypomethylating Agent

Phase 2
Terminated
Conditions
Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome
Chronic Myelomonocytic Leukemia
Previously Treated Myelodysplastic Syndrome
Recurrent Acute Myeloid Leukemia With Myelodysplasia-Related Changes
Recurrent Adult Acute Myeloid Leukemia
Interventions
Drug: Azacitidine
Drug: Decitabine
Other: Laboratory Biomarker Analysis
Other: Pharmacological Study
Biological: Recombinant EphB4-HSA Fusion Protein
First Posted Date
2017-05-10
Last Posted Date
2019-04-18
Lead Sponsor
University of Southern California
Target Recruit Count
7
Registration Number
NCT03146871
Locations
🇺🇸

USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States

CX-01 Combined With Azacitidine in the Treatment of Relapsed or Refractory Myelodysplastic Syndrome and Acute Myeloid Leukemia

Phase 1
Completed
Conditions
Acute Myeloid Leukemia
Myelodysplastic Syndromes
MDS
AML
Interventions
Drug: CX-01
Drug: Azacitidine
Procedure: Bone marrow biopsy
Procedure: Peripheral blood draw
First Posted Date
2016-12-16
Last Posted Date
2019-12-05
Lead Sponsor
Washington University School of Medicine
Target Recruit Count
20
Registration Number
NCT02995655
Locations
🇺🇸

Washington University School of Medicine, Saint Louis, Missouri, United States

Ipilimumab and Decitabine in Treating Patients With Relapsed or Refractory Myelodysplastic Syndrome or Acute Myeloid Leukemia

Phase 1
Active, not recruiting
Conditions
Previously Treated Myelodysplastic Syndrome
Recurrent Acute Myeloid Leukemia
Recurrent Acute Myeloid Leukemia, Myelodysplasia-Related
Recurrent Myelodysplastic Syndrome
Secondary Acute Myeloid Leukemia
Secondary Myelodysplastic Syndrome
Refractory Acute Myeloid Leukemia
Refractory Myelodysplastic Syndrome
Interventions
First Posted Date
2016-09-07
Last Posted Date
2025-01-07
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
54
Registration Number
NCT02890329
Locations
🇺🇸

Northside Hospital, Atlanta, Georgia, United States

🇺🇸

University of Virginia Cancer Center, Charlottesville, Virginia, United States

🇺🇸

Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States

and more 8 locations

Selinexor With Fludarabine and Cytarabine for Treatment of Refractory or Relapsed Leukemia or Myelodysplastic Syndrome

Phase 1
Completed
Conditions
Acute Myeloid Leukemia (AML)
Acute Lymphoblastic Leukemia (ALL)
Myelodysplastic Syndrome (MDS)
Mixed Phenotype Acute Leukemia (MPAL)
Interventions
Drug: Selinexor
Drug: Fludarabine
Drug: Cytarabine
Drug: methotrexate/hydrocortisone/cytarabine
First Posted Date
2014-08-08
Last Posted Date
2020-03-26
Lead Sponsor
St. Jude Children's Research Hospital
Target Recruit Count
19
Registration Number
NCT02212561
Locations
🇺🇸

St. Jude Children's Research Hospital, Memphis, Tennessee, United States

🇺🇸

Cook Children's Medical Center, Fort Worth, Texas, United States

🇺🇸

Phoenix Children's Hospital, Phoenix, Arizona, United States

and more 3 locations

Safety and Pharmacokinetics Study of SyB C-1101 in Patients With Recurrent/Relapsed or Refractory Myelodysplastic Syndrome (MDS)

Phase 1
Completed
Conditions
Myelodysplastic Syndrome
Interventions
Drug: SyB C-1101
First Posted Date
2013-12-17
Last Posted Date
2022-11-21
Lead Sponsor
SymBio Pharmaceuticals
Target Recruit Count
10
Registration Number
NCT02014051
Locations
🇯🇵

Research site, Kyoto, Japan

Long Term Safety Study of SyB C-1101 in Patients With Recurrent/Relapsed or Refractory Myelodysplastic Syndrome (MDS) - Extension Study

Phase 1
Completed
Conditions
Myelodysplastic Syndrome
Interventions
Drug: SyB C-1101
First Posted Date
2013-12-06
Last Posted Date
2017-02-23
Lead Sponsor
SymBio Pharmaceuticals
Target Recruit Count
1
Registration Number
NCT02002936
Locations
🇯🇵

Research Site, Kyoto, Japan

Long Term Safety Study of SyB L-1101 in Patients With Recurrent/Relapsed or Refractory Myelodysplastic Syndrome (MDS) - Extension Study

Phase 1
Completed
Conditions
Myelodysplastic Syndrome
Interventions
Drug: SyB L-1101
First Posted Date
2013-12-03
Last Posted Date
2017-03-31
Lead Sponsor
SymBio Pharmaceuticals
Target Recruit Count
1
Registration Number
NCT02000154
Locations
🇯🇵

Research Site, Tokyo, Japan

🇯🇵

Research site, Isesaki, Kanagawa, Japan

© Copyright 2025. All Rights Reserved by MedPath